Delayed seroma formation secondary to docetaxel

Area of Science:

• Oncology
• Pharmacology
• Surgical Complications

Background:

• Docetaxel is a key chemotherapy agent used for metastatic and node-positive breast cancer, functioning by stabilizing microtubules and inhibiting mitosis.
• Common side effects of docetaxel include neutropenia and fluid retention, which are generally manageable.
• Postoperative fluid collections, such as seromas, are known complications, particularly after procedures like latissimus dorsi flap harvest.

Observation:

• A case report details a patient developing a seroma four years after breast reconstructive surgery.
• This patient had received docetaxel treatment years subsequent to her reconstructive procedure.
• Late recurrence or new onset of localized fluid collections years post-surgery is an unusual clinical presentation.

Findings:

• The study highlights a potential, albeit unproven, association between docetaxel treatment and the late development of seroma.
• While a definitive causal link is not established, the temporal relationship suggests docetaxel as a possible contributing factor.
• This contrasts with the typical acute or early postoperative occurrence of seromas.

Implications:

• Clinicians should consider docetaxel as a potential factor in the development of late-onset seromas in patients with a history of breast cancer treatment and surgery.
• Further investigation may be warranted to elucidate the mechanism and confirm the relationship between docetaxel and delayed fluid collection.
• Awareness of this potential side effect can aid in the appropriate management and monitoring of patients undergoing breast cancer therapy and reconstruction.